Coya Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Coya Therapeutics, Inc. (COYA) reported Increase (Decrease) in Accounts Payable of -$96.04 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-11
- Coya Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $58.67K.
- Coya Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$154.71K, a 251.86% decline year-over-year.
- Coya Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$50.58K, a 104.04% decline year-over-year.
- Coya Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $180.36K.
- Coya Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$527.01K, a 210.38% decline from fiscal 2024.
- Coya Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was $477.45K, a 59.78% increase from fiscal 2023.
- Coya Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was $298.82K, a 64.65% decline from fiscal 2022.
- Coya Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was $845.28K, a 27.08% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $58.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$96.04K 10-Q · filed 2026-08-11 | -$146.62K derived: sum of 3 quarters · filed 2026-08-11 | $33.73K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$154.71K 10-Q · filed 2026-05-12 | -$205.29K derived: sum of 2 quarters · filed 2026-05-12 | -$24.93K derived: sum of 3 quarters · filed 2026-05-12 | -$783.60K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$50.58K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $129.78K derived: sum of 2 quarters · filed 2026-03-16 | -$628.88K derived: sum of 3 quarters · filed 2026-08-11 | -$527.01K 10-K · filed 2026-03-16 |
| 2025-09-30 | $180.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$578.30K derived: sum of 2 quarters · filed 2026-08-11 | -$476.43K 10-Q · filed 2025-11-12 | $774.98K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$758.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$656.78K 10-Q · filed 2026-08-11 | $594.62K derived: sum of 3 quarters · filed 2026-08-11 | -$895.40K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $101.88K 10-Q · filed 2026-05-12 | $1.35M derived: sum of 2 quarters · filed 2026-05-12 | -$136.74K derived: sum of 3 quarters · filed 2026-05-12 | $102.06K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$238.62K derived: sum of 2 quarters · filed 2026-03-16 | $185.00 derived: sum of 3 quarters · filed 2026-03-16 | $477.45K 10-K · filed 2026-03-16 |
| 2024-09-30 | -$1.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.25M derived: sum of 2 quarters · filed 2025-11-12 | -$773.96K 10-Q · filed 2025-11-12 | -$297.23K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $238.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $716.07K 10-Q · filed 2025-08-12 | $1.19M derived: sum of 3 quarters · filed 2025-08-12 | $1.59M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $477.26K 10-Q · filed 2025-05-13 | $953.99K derived: sum of 2 quarters · filed 2025-05-13 | $1.35M derived: sum of 3 quarters · filed 2025-05-13 | $1.05M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $476.73K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $873.10K derived: sum of 2 quarters · filed 2025-03-18 | $568.93K derived: sum of 3 quarters · filed 2025-03-18 | $298.82K 10-K · filed 2025-03-18 |
| 2023-09-30 | $396.37K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $92.20K derived: sum of 2 quarters · filed 2024-11-06 | -$177.91K 10-Q · filed 2024-11-06 | $211.19K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$304.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$574.28K 10-Q · filed 2024-08-12 | -$185.18K derived: sum of 3 quarters · filed 2024-08-12 | -$132.61K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$270.11K 10-Q · filed 2024-05-09 | $119.00K derived: sum of 2 quarters · filed 2024-05-09 | $171.56K derived: sum of 3 quarters · filed 2024-05-09 | $941.65K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $389.11K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $441.67K derived: sum of 2 quarters · filed 2024-03-19 | $1.21M derived: sum of 3 quarters · filed 2024-03-19 | $845.28K 10-K · filed 2024-03-19 |
| 2022-09-30 | $52.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $822.65K derived: sum of 2 quarters · filed 2023-11-08 | $456.18K 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $770.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $403.61K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$366.48K 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $665.17K 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |